TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06696547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
Study: NCT05898594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose Computed Tomography
Description: Per standard care
Study: NCT06697665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM103
Description: Patients were treated with PD-1, cyclophosphamide and fludarabine, LM103 and IL-2 treatment.
Study: NCT04963413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Description: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Study: NCT04919590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: This is Quitting
Description: Text message-based intervention for quit vaping support.
Study: NCT06696235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early initiation of continuous renal replacement therapy
Description: Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard initiation of continuous renal replacement therapy
Description: Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
Study: NCT06696495

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of the size and width of the foot
Description: Assessment of the height of the plantar arch using a podoscope, and application of functional scales such as the AOFAS (Ankle and Foot Outcome Score), the FPI (Foot Posture Index) and the FFI (Foot Function Index). In addition, the distribution of plantar pressure and the centre of pressure (COP)
Study: NCT06697223

Intervention type: DEVICE
Group type: OTHER
Intervention: INTERCEPT Blood System for Platelets with LED Illuminator
Description: Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) using the LED Illuminator and stored for 5 days at 20 to 24°C with continuous agitation.
Study: NCT06782373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Supplied in hard capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Supplied in hard capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Supplied in hard capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied in hard capsules.
Study: NCT06780085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Raludotatug Deruxtecan
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetetaxel
Description: IV Infusion
Study: NCT04689048

Intervention type: DRUG
Group type: OTHER
Intervention: 18F fluciclovine
Description: Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
Study: NCT06396195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bioflx crown
Description: The Bioflx crowns are characterized by their flexibility, durability, and adaptability. These crowns are preformed pediatric crowns designed for aesthetics, combining properties found in both stainless steel and zirconia crowns.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stainless steel crown
Description: Stainless steel crowns continue to be considered the Gold Standard for posterior full coverage restorations in primary molars
Study: NCT04919590

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment only control
Description: Assessment only

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: No contact until follow-up survey, waitlisted to receive intervention post study
Study: NCT04861922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unfractionated Heparin
Description: 10 unit/kgBW/hour continuous infusion for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin
Description: 10 unit/kgBW/hour continuous infusion for 5 days
Study: NCT04922021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by injection just under the skin.
Study: NCT06512038

Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA Scan
Description: If the participant consents to take part in the trial, they will have an additional DEXA scan.
Study: NCT05346224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX11
Description: Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Perjeta®
Description: Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
Study: NCT04969770

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound elastography (USE)
Description: Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound elastography (USE)
Description: Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography (USE)
Description: Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation.
Study: NCT06380400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot bath
Description: Pregnant women were given footbaths for 20 minutes during the active phase of the first stage of labour (after cervical dilatation of 4 cm) and 20 minutes during the transitional phase of the second stage of labour (cervical dilatation of 9 cm). Pregnant women who completed two footbath sessions were assessed for pain using the visual comparison scale. In addition, the data collection process will be completed by applying the Birth Comfort Scale after the two stages of labour.
Study: NCT05611684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Losenatide
Description: Treatment 0.2mg QW for 12 weeks
Study: NCT05312905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: Mirror Therapy applied alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy + Cognitive Therapy
Description: Mirror Therapy supported with Cognitive Exercises
Study: NCT03000803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.
Study: NCT06497426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study intervention
Description: Participants will be asked to drink water. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance.
Study: NCT05598996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COT-Based Intervention
Description: The COT-based approach uses a controller that runs case-by-case dynamical systems simulations modeling based on answers to daily questions rooted in social cognitive theory to produce ambitious but achievable daily adaptive step goal recommendations. The process for the COT-based approach is as follows: Phase 1) 2-week measurement only; Phase 2) open-loop system identification experiment (meant to create individualized dynamical models for each participant); Phase 3) closed-loop experiment to optimize for PA initiation, and Phase 4) closed-loop experiment to optimize for PA maintenance.
Study: NCT04922021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
Study: NCT05603910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules taken daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated External Beam Radiation Therapy
Description: HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
Study: NCT04800835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Balloon
Description: implantation of two types of gastric balloons. Spatz3 Adjustable balloon will be implanted for 12 months and 6-month non adjustable balloon will be implanted for 6 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Balloon
Description: implantation of two types of gastric balloons. Spatz3 Adjustable balloon will be implanted for 12 months and 6-month non adjustable balloon will be implanted for 6 months
Study: NCT04942483

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood eosinophil count
Description: Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Atopic sensitization
Description: Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
Study: NCT06532552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACl
Description: Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACh
Description: Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
Study: NCT04942483

Intervention type: DIAGNOSTIC_TEST
Intervention: FeNO (offline method)
Description: The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
Study: NCT06402227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gamified instruction
Description: At the beginning, the speaker played the role of a laboratory rescue team, narrated the background story of the board game, and led the children into the game situation. Then, the speaker explained four types of pathogens, which the investigators defined them according to different types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker explained their characteristics and key points, representative diseases in real life, corresponding prevention methods and so on. The lecture lasted for 15 minutes, then the children were divided into different groups to play the board game for about 20 minutes. During the game, students were required to collect Prevention Method Cards made by the research team. Students must perform the correct behavior of infection control or answer questions related to the class content in order to obtain the card and win.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional lesson lecture
Description: The lecture was about 35 minutes. At the beginning, the speaker explained the terms to children, including infectious diseases, symptoms and pathogens. Next, the speaker introduced the components of the infection chain and how to make infection control behaviors for different parts of it. Then the speaker focused on the four types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker illustrated their characteristics and key points, representative diseases in real life, and corresponding prevention methods. In the end, the speaker led the students to practice infection control behaviors, such as the seven correct steps of washing hands, the right steps for wearing and taking off masks, and exercises that can be done to increase immunity.
Study: NCT04678167

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Caloric test
Description: Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Caloric test
Description: Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Caloric test
Description: Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of the speed of Nystagmus
Description: A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
Study: NCT05162040

Intervention type: DEVICE
Intervention: Use of PedaleoVR
Description: All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application.
Study: NCT04518943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
Study: NCT04678167

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measurement of the speed of Nystagmus
Description: A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
Study: NCT04518943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
Study: NCT05782556

Intervention type: DEVICE
Intervention: Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)
Description: For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
Study: NCT04981340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: Same as previously described

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard urotherapy
Description: Same as previously described
Study: NCT04518943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
Study: NCT04981340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard urotherapy
Description: Same as previously described